|By PR Newswire||
|March 10, 2014 02:29 PM EDT||
LONDON, March 10, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
This research service provides a list of key technology trends in health and wellness that are likely to have an impact in the year 2013 until 2017. The slides provide a brief snapshot of the technology, the key benefits or strengths, trends and initiatives, key stakeholders and their solutions, applications, enabling technologies, insights and recommendations as applicable for the identified list of technologies.
Research Scope and Index
Top Technology Trends:
Targeted Drug Delivery
Recombinant Expression Systems
Technical Insights division of Frost & Sullivan evaluated technology trends in the Health and Wellness sector and has identified top technology trends that are likely to have an impact in the year 2013.
The slides provide information on the following lines on a best effort basis, as applicable to the technology under consideration.
They are as follows:
• Brief Snapshot of the Technology
• Recent Developments
• Key Stakeholders and their Solutions
• Future Scenario
•Strategic Decision Makers
•Technology Policy Heads
•Market Research Reports
•Technology Policy information Sites
•Thought Leader Briefings
Personalized medicine involves the study of human diseases at molecular level, pairing the advances in molecular diagnostics, along with genomics based drug development. Particular treatment design according to the individual's genome and epigenome is the goal.
As the aging population grows and seeks more services for disease screening, diagnosis and monitoring, the demand for novel life sciences tools increases.
•Personalized medicine (PM) aims to characterize disease at different levels and evolution stages to target specific genes or molecular pathways.
•Miniaturized, wireless, implantable sensors, are finding increased opportunities to more conveniently provide real-time information about a patient's condition.
•Omics-based technologies have revolutionized life sciences research and biomedical engineering, by generating huge amounts of information.
•Important efforts are being conducted toward becoming this information in valuable insights for clinical and biomedical routine tools for early diagnostics and prognostics.
Year of Impact
•Personalized medicine involves an evolving challenge from part of a broad spectrum of fields of research covering both sciences traditionally contributing to medicine and healthcare advances, such as genetics, biology, and pharmacology, and their -omics related fields, that is, proteomics, transcriptomics, metabonomics, and so on.
•More recently contributing sciences, such as bioinformatics, robotics, nanobiotechnology, mechatronics, and biomics, also play a critical role in the impact of personalized medicine in the human health.
•A solid convergence of these technologies is expected by 2016 for commercialization and 2018 for wide scale adoption.
•Personalized medicine (PM) deeply digs inside the study of human diseases at molecular level, pairing the advances in molecular diagnostics, as well as, genomics based drug development. The aim of PM is to harmonize the relation between treatment and patient, taking into consideration the individual variations that lead to a specific behavior and drug response, could even involve the particular treatment design according to the individual genotype among other features.
•Toward this concept, coined terms as stratified medicine and integrated healthcare attempt to cover developments in genomics-based personalized medicines for different clusters, predisposition testing, preventive medicine, combination of diagnostics with therapeutics, and monitoring of therapy.
•A new vision attempting to avoid costly and prolonged trial and error approaches, while precluding treatment side effects, in conjunction with significant gain time, is being achieved.
•Personalized diagnostics and therapeutics
•Response drug evaluation and screening for new, more specific molecular entities
•Facing rare disease challenges for novel solutions
•Addressing autoimmune and inflammatory diseases therapies
•Attrition rate, risk, cost and time reduction
•Use of virtual clinical trials and more caution experimental design for stratified groups
•Holistic view of human health
•New niches for molecular entities
Technology Roadmap (2000-2020)
1. Stratified Medicine
Gene expression/disease correlation
Pathways modeling/simulation and biomarkers development
Focus on cancer research
In silico, in vitro, in vivo models for experimental design and clinical trials
2. Personalized Theranostics
Single molecule biosensors
Systems biology/Modeling and simulation
Micro/nanotech for cancer/infectious diseases diagnostics
Flexible assay platform (platform independence)
Multipanel biomarker assays
3. Virtual Patients
Virtual populations for clinical trials
Disease prediction and risk management
Targeted tumor therapeutics
Epigenome-based tech platforms
In silico early diagnostic tests
Pathway regulation therapeutics
Circulating customized microvesicle-based cancer testing
Technology Development and Adoption Footprint
Pioneering in PM, the US possess one of the strongest R&D networks, counting with solid and well established public and private funding sources
The EU is remarkable promoting the advancement of PM approaches through its numerous FP7 programmes. In turn, national ecosystems are also emerging
Japan, India and Australia lead the development of PM, not only in a direct manner, but also promoting the development of enabling cutting-edge technologies
Marshfield Clinic, Wisconsin, US: Establishment of the Center for Medical Genetics, Personalized Medicine Research Center, Personalized Medicine Research Project (PMRP), Wisconsin Genomics Initiative (WGI). University of California San Francisco (UCSF), US: Collaboration line with Kaiser Permanente (an insurance company) to expand its existing data bank of clinical information to include genetic sequencing information. Launch of the Research Program on Genes, Environment and Health (RPGEH) initiative, and the Pharmacogenomics Research Network'(PGRN). University of Chicago, US: Launch of the 1200 Patients Project to pave the way for introducing the PM approach in the clinical routine. Mayo Clinic;, US: Creation of the Center for Individualized Medicine, with its Translational and Infrastructure programmes. Etc.
Indiana Center for Systems Biology and Personalized Medicine, Center for Integration of Medicine & Innovative Technology (CIMIT)-Massachusetts General Hospital (MGH), Integrated Biobank of Luxembourg (IBBL), Fraunhofer Institute for Systems and Innovation Research, Institut national de la santé et de la recherche médicale (Inserm), The Institute for Personalized Respiratory Medicine of the University of Illinois Hospital and Health Sciences System, Interuniversity Microelectronics Centre(IMEC), etc.
Affymetrix, Cynvenio, DNA Genotek, Genia, Illumina, Life Technologies, Amgen, Astellas, BI, BMS, Eli Lilly, EMD Serono, Endo Health Solutions, GE, GSK, J&J, Merck, Millennium, Novartis, Pfizer, Atossa Genetics, Fluxion, Nodality, 23andMe, Cureline, Genophen, iSpecimen, N-of-One, Selventa, Kinemed, etc.
Government Agencies/Funding Bodies
Agencies financially supporting PM projects: The Biomedical Information Science and Technology Initiative (NIH/BISTI), National Institute of General Medical Sciences (NIH/NIGMS), Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS), Small Business Innovation Research (SBIR), Small Business Technology Transfer Program (STTR), European Commission (EU), European Research Council (ERC), European Science Foundation (ESF), European Association for Predictive, Preventive and Personalised Medicine (EPMA), European Organisation of Personalised Medicine (EPEMED), Asia-Pacific Economic Cooperation (APEC), which through their multiple framework programmes hold strong focus on PM envisioning 2020. VCs: Burrill & Company, Kleiner Perkins Caufield & Byers, Mohr Davidow, Pappas Ventures, Third Rock Ventures, LLC
Regulators/ Associations/Standardization Bodies
FDA and EMA have issued draft guidelines on registration and approval procedures regarding patient populations stratification to facilitate targeted therapy.
Table of Contents
Executive Summary 3
Personalized Medicine 6
Targeted Drug Delivery 16
Regenerative Medicine 26
Next-Generation Prebiotics 46
Nutrient Encapsulation 51
Nanoparticle-based Therapies 56
Next-Generation Sequencing 66
Recombinant Expression Systems 72
The Frost & Sullivan Story 77
Read the full report:
Top Technologies in Health and Wellness